作者:潘妍出品:全球财说近期,一家围绕患者“诊前-诊中-诊后”全生命周期的互联网医疗平台微脉向港交所递交招股书,拟登陆主板市场,由招商证券(香港)与德意志证券担任联席保荐人。按2024年收入计,微脉是中国第三大全病程健康管理服务提供商,且为中国最大的客户导向的AI赋能的全病程健康管理服务提供商。然而,透过微脉的招股书看到的却是:市占率仅0.71%的全病程健康管理服务提供商龙头企业,重资产模式下的...
Source Link作者:潘妍出品:全球财说近期,一家围绕患者“诊前-诊中-诊后”全生命周期的互联网医疗平台微脉向港交所递交招股书,拟登陆主板市场,由招商证券(香港)与德意志证券担任联席保荐人。按2024年收入计,微脉是中国第三大全病程健康管理服务提供商,且为中国最大的客户导向的AI赋能的全病程健康管理服务提供商。然而,透过微脉的招股书看到的却是:市占率仅0.71%的全病程健康管理服务提供商龙头企业,重资产模式下的...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.